Refractive error is among the leading causes of visual impairment globally. The diagnosis and management of refractive error has traditionally relied on comprehensive eye examinations by eye care professionals, but access to these specialized services has remained limited in many areas of the world. Given this, artificial intelligence (AI) has shown immense potential in transforming the diagnosis and management of refractive error. We review AI applications across various aspects of refractive error care – from axial length prediction using fundus images to risk stratification for myopia progression. AI algorithms can be trained to analyze clinical data to detect refractive error as well as predict associated risks of myopia progression. For treatments such as implantable collamer and orthokeratology lenses, AI models facilitate vault size prediction and optimal lens fitting with high accuracy. Furthermore, AI has demonstrated promise in optimizing surgical planning and outcomes for refractive procedures. Emerging digital technologies such as telehealth, smartphone applications, and virtual reality integrated with AI present novel avenues for refractive error screening. We discuss key challenges, including limited validation datasets, lack of data standardization, image quality issues, population heterogeneity, practical deployment, and ethical considerations regarding patient privacy that need to be addressed before widespread clinical implementation.

Ophthalmic diseases such as glaucoma, age-related macular degeneration (ARMD), and optic neuritis involve complex molecular and cellular disruptions that challenge current diagnostic and therapeutic approaches. Advanced artificial intelligence (AI) and machine learning (ML) models offer a novel lens to analyze these diseases by integrating diverse datasets, identifying patterns, and enabling precision medicine strategies. Over the past decade, applications of AI in ophthalmology have expanded from imaging-based diagnostics to molecular-level modeling, bridging critical gaps in understanding disease mechanisms. This paper systematically reviews the application of AI-driven methods, including reinforcement learning (RL), graph neural networks (GNNs), Bayesian inference, and generative adversarial networks (GANs), in the context of these ophthalmic conditions. RL models simulate transcription factor dynamics in hypoxic or inflammatory environments, offering insights into disrupted molecular pathways. GNNs map intricate molecular networks within affected tissues, identifying key inflammatory or degenerative drivers. Bayesian inference provides probabilistic models for predicting disease progression and response to therapies, while GANs generate synthetic datasets to explore therapeutic interventions. By contextualizing these AI tools within the broader framework of ophthalmic disease management, this review highlights their potential to transform diagnostic precision and therapeutic outcomes. Ultimately, this work underscores the need for continued interdisciplinary collaboration to harness AI’s potential in advancing the field of ophthalmology and improving patient care.